Cited by 371Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsNeurological Disease Mechanisms and Treatments

Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model

Open access
Zhong, Li, Xu, Ying, Zhuo, Rengong, Wang, Tingting, Wang, Kai, Huang, Ruizhi, Wang, Daxin, Gao, Yue +15 more·2019·Nature Communications

Abstract

Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial surface receptor genetically linked to the risk for Alzheimer's disease (AD). A proteolytic product, soluble TREM2 (sTREM2), is abundant in the cerebrospinal fluid and its levels positively correlate with neuronal injury markers. To gain insights into the pathological roles of sTREM2, we studied sTREM2 in the brain of 5xFAD mice, a model of AD, by direct stereotaxic injection of recombinant sTREM2 protein or by adeno-associated virus (AAV)-mediated expression. We found that sTREM2 reduces amyloid plaque load and rescues functional deficits of spatial memory and long-term potentiation. Importantly, sTREM2 enhances microglial proliferation, migration, clustering in the vicinity of amyloid plaques and the uptake and degradation of Aβ. Depletion of microglia abolishes the neuroprotective effects of sTREM2. Our study demonstrates a protective role of sTREM2 against amyloid pathology and related toxicity and suggests that increasing sTREM2 can be explored for AD therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09118-9

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Increased sTREM2 inhibits fibrillization of Aβ peptides, increases uptake of Aβ fibrils into microglial cells, and attenuates cognitive and clinical decline in AD patients and AD mouse models.

    “Epidemiologic study of AD patients revealed that increased sTREM2 was shown to be beneficial: it can inhibit the fibrillization of Aβ peptides, increase the uptake of Aβ fibrils into microglial cells,235 and attenuate cognitive and clinical decline in AD patients and AD mouse models.236,237”

    From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [237]

    The Discussion (page not provided) reports that sTREM2 ameliorated memory deficits in 5×FAD mice, supporting the mouse-model portion. The paper does not report that increased sTREM2 attenuates cognitive or clinical decline in AD patients; its Introduction discusses patient CSF levels, not a clinical benefit. The fibrillization and microglial-uptake clauses are attached to citation 235, rather than this source's citation. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Loss of function due to the presence of the Trem2 R47H mutation increases the chance of AD reaching the stage of diagnosis.

    “loss of function due to the presence of the Trem2 R47H mutation increasing the chance of AD reaching the stage of diagnosis (44,104–107)”
  • Increased expression of TREM2 in Alzheimer's disease has a protective function slowing disease progression.

    “Our findings are thus compatible with increased expression of TREM2 in Alzheimer’s disease having a protective function slowing disease progression”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zhong, L., Xu, Y., Zhuo, R., Wang, T., Wang, K., Huang, R., Wang, D., Gao, Y., Zhu, Y., Sheng, X., Chen, K., Wang, N., Zhu, L., Can, D., Marten, Y., Shinohara, M., Liu, C.-C., Du, D., Sun, H., Wen, L., Xu, H., Bu, G., & Chen, X.-F.
Affiliations
  • Xiamen University (CN)
  • Mayo Clinic (US)
  • Sanford Burnham Prebys Medical Discovery Institute (US)
Corresponding author
  • Bu, Guojun
  • Chen, Xiao-Fen
Venue
Nature Communications
Published
2019-03-25
Volume
10
Issue
1
Pages
1365-1365
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2924084484
Cited by
371
References
68
Citations by year
2026: 31 · 2025: 44 · 2024: 59 · 2023: 67 · 2022: 67 · 2021: 38 · 2020: 47 · 2019: 17
FWCI
18.61
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
Funders
  • National Natural Science Foundation of China (81370459, 81601227, 81373999, 81774377, 31400914, 81701079)
  • National Institutes of Health
  • Japan Society for the Promotion of Science (16H06277)
  • National Institute on Aging (RF1AG056130, R37AG027924, RF1AG056114, R01AG035355)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
soluble TREM2, Alzheimer's disease, microglia, amyloid plaques, amyloid-beta clearance, spatial memory, long-term potentiation, 5xFAD mice, neuroprotection, cerebrospinal fluid biomarkers, AAV gene delivery
MeSH terms
Dependovirus, Alzheimer Disease, Animals, Animals, Newborn, Brain, Cell Movement, Disease Models, Animal, Female, Genetic Vectors, Humans, Injections, Intraventricular, Male, Membrane Glycoproteins, Neurons, Peptide Fragments, Phenotype, Receptors, Immunologic, Recombinant Fusion Proteins, Stereotaxic Techniques, Gene Expression, Amyloid beta-Peptides, Microglia, Long-Term Potentiation, Cell Proliferation, Green Fluorescent Proteins, Mice, Plaque, Amyloid, Proteolysis, Primary Cell Culture, Spatial Memory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review